SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

FELDAN THERAPEUTICS REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATE

FLD-103 was generally well tolerated across all dose cohorts; no maximum tolerated dose was reached.

Related stories